Piramal Pharma Limited has completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based contract development and manufacturing organisation (CDMO) specialising in vaccines and biologics.

The transaction, completed on 18 August 2026, involved a cash consideration of ₹76 crore (approximately US$7.95 million). Following the acquisition, Piramal Pharma now owns 74% of Yapan Bio, making the company a subsidiary.

The acquisition strengthens Piramal Pharma's capabilities in the biologics sector by integrating Yapan Bio's large-molecule expertise into the company's broader service offering. Yapan Bio will continue to operate under Piramal Pharma Solutions (PPS), the company's CDMO business.

The expanded capabilities are expected to support the development and manufacturing of complex biologic therapies, while helping customers scale programmes more efficiently.

Yapan Bio also contributes to ADCelerate™, PPS's fixed-price integrated platform for Phase I antibody-drug conjugate (ADC) development. The platform is designed to support ADC programmes from research and development through to GMP manufacturing in as little as 12 months.

The acquisition is expected to strengthen ADCelerate™ and expand Piramal Pharma's ability to support the development and manufacturing of ADC therapies.

 

Source: prnewswire.com

Report Abuse